Affini-T will leverage ElevateBio BaseCamp's LentiPeakTM lentiviral vector technology platform and cell therapy production capabilities to advance its investigational oncogenic driver programs into clinical development.
ElevateBio BaseCamp is a purpose-built viral vector and cell therapy center of excellence with end-to-end process development and current Good Manufacturing Practice manufacturing capabilities for research, clinical and commercial cell and gene therapies, and regenerative medicines.
Affini-T's proprietary platform is designed to select and engineer the right immune cells to orchestrate a durable and coordinated immune response within the immunosuppressive tumor microenvironment.
The company is pioneering engineered T cell therapies with cutting-edge synthetic biology and gene editing enhancements to target oncogenic driver mutations at the core of tumor biology.
Its engineered cell therapies are designed to overcome the immunosuppressive tumor microenvironment, enhancing T cell function to increase durability, build persistent responses, and augment tumor infiltration.
Affini-T's investigational cell therapies have the potential to offer new treatment options for patients affected by cancer with mutant variants of KRAS, which account for up to 30% of all cancers and are particularly frequent in cancers with high mortality rates, including lung cancer, colorectal cancer, and pancreatic cancer.
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come.
The company has assembled talent, built facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines.
In addition, ElevateBio BaseCamp in Waltham, Massachusetts, is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice manufacturing capabilities.
It was designed to support diverse cell and gene therapy products, including autologous, allogeneic, and regenerative medicine cell products and viral vector manufacturing capabilities.
Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines.
ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib